The last Phase II announcement (released at 9:02 am on Monday, 18 December) was titled "P2 trial shows significant improvements in Phelan-McDermid". The key points were that "significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures" and "NNZ-2591 was safe and well tolerated, with no clinically significant changes in laboratory values or other safety parameters during treatment".
The share price closed up $5.06 (29.52%). It will be interesting to see how today's announcement compares in substance and effect on the share price. As others have noted, there is a case to be made that positive results today would be more valuable than the last announcement, since it would indicate that NNZ-2591 has potential across multiple indications.
The last Phase II announcement (released at 9:02 am on Monday,...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.50 |
Change
0.000(0.00%) |
Mkt cap ! $2.492B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 219 | $20.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.50 | 89 | 1 |
View Market Depth
| Last trade - 09.47am 10/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable